Sylvester Comprehensive Cancer Center


Radioimmunotherapy Now Available As Outpatient Treatment for Lymphoma at UM/Sylvester


Two new dual-action radioimmunotherapy agents, Bexxar and Zevalin, are now available as outpatient therapies to some patients with low-grade or transformed non-Hodgkin’s lymphoma at the University of Miami Sylvester Comprehensive Cancer Center. Each drug is a unique dual-action therapy that combines a radioactive isotope and an immunological antibody into one treatment, using both radiation therapy and the patient’s own immune system to fight cancer.